Update on taxane development: New analogs and new formulations

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 371-384

  Yared, Jean A ^a   Tkaczuk, Katherine H R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

New antimicrotubule agents; New taxane formulations; Novel taxanes; Taxane analogs; Taxane(s)

Indexed keywords

7 METHYLTHIOMETHYLPACLITAXEL; ALBUMIN; ANTIEMETIC AGENT; BEVACIZUMAB; CABAZITAXEL; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CREMOPHOR; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; ERIBULIN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; GLUTAMIC ACID; IXABEPILONE; LAROTAXEL; LIPOSOME; MITOXANTRONE; NANOPARTICLE; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYMER; SOLVENT; TAXANE DERIVATIVE; TAXOID; TESETAXEL; UNINDEXED DRUG; VINFLUNINE;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESEARCH; DRUG SYNTHESIS; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HUMAN; LETHARGY; LEUKEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MYALGIA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; WEAKNESS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG APPROVAL; DRUG DESIGN; HUMANS; NEOPLASMS; PACLITAXEL; TAXOIDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872288933     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S28997     Document Type: Review

References (75)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
2. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598.
3. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665-685.
4. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8: 1038-1044.
5. Desai N, Trieu V, Yao R. Evidence of greater antitumor activity of cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: role of novel albumin transporter mechanism. Breast Cancer Res Treat. 2003;8:1038-1044.
6. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
7. Gradishar WJ, Krasnojon D, Cheporov S, et al. Signifcantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611-3619.
8. Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2012;30:CRA1002.
9. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723-730.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
11. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 2010;5:395-402.
12. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003;94:459-466.
13. Baas P, Szczesna A, Albert I, et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:745-750.
14. Saif M W, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68: 1565-1573.
15. Singer JW, Baker B, De Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol. 2003;519:81-99.
16. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998;58:2404-2409.
17. Li C, Price JE, Milas L, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res. 1999;5:891-897.
18. Mita M, Mita A, Sarantopoulos J, et al. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2009;64:287-295.
19. O'Brien ME, Socinski MA, Popovich AY, et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:728-734.
20. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:623-630.
21. Paz-Ares L, Ross H, O'Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98:1608-1613.
22. Sabbatini P, Sill M W, O'Malley D, Adler L, Secord AA, Gynecologic Oncology Group Study. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;111:455-460.
23. US National Institutes of Health. Phase III Randomized Study of Paclitaxel Versus Polyglutamate Paclitaxel as Consolidation/Maintenance Therapy Versus No Further Anticancer Therapy Until Disease Progression in Patients With Stage III or IV Ovarian Epithelial or Primary Peritoneal Cancer or Fallopian Tube Cancer. Available from: http://cancer.gov/clinicaltrials/GOG-0212. Accessed April 26, 2012.
24. Jeyapalan SA, Goldmann M, Donahue J, et al. A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. ASCO Meeting Abstracts. 2011;29:2036.
25. US National Institutes of Health. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01402063?term=glioblastoma+radiation+brown&recr=Open&no_unk=Y&rank=1. Accessed April 26, 2011.
26. Dipetrillo T, Suntharalingam M, Ng T, et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2012;35:64-67.
27. Lin NU, Parker LM, Come SE, et al. Phase II study of CT-2103 as firstor second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007;25:369-375.
28. Thurston G, McLean J W, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic infammation in mice. J Clin Invest. 1998;101:1401-1413.
29. Strieth S, Eichhorn ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004;110:117-124.
30. Strieth S, Nussbaum C F, Eichhorn ME, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer. 2008;122:452-460.
31. Strieth S, Eichhorn ME, Werner A, et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic effcacy in combination with Cisplatin. Clin Cancer Res. 2008;14:4603-4611.
32. Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem. 2005;1:125-139.
33. Bode C, Trojan L, Weiss C, et al. Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep. 2009;22:321-326.
34. Eichhorn ME, Ischenko I, Luedemann S, et al. Vascular targeting by EndoTAG-1 enhances therapeutic effcacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer. 2010;126:1235-1245.
35. Löhr JM, Haas SL, Bechstein WO, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-1222.
36. Awada A, Bondarenko I, Tarasova O, et al. Results of the first randomized phase II study of cationic liposomal paclitaxel (EndoTAG-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 2010;21(8); 85 (Abstr LBA12).
37. Bissery M, Vrignaud P, Combeau C, et al. Preclinical evaluation of XRP9881A, a new taxoid. AACR Meeting Abstracts. 2004;2004:1253a.
38. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des. 2001;7:1251-1257.
39. Zatloukal P, Gervais R, Vansteenkiste J, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol. 2008;3:894-901.
40. Dieras V, Limentani S, Romieu G, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008;19:1255-1260.
41. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and effcacy. J Control Release. 2001;72:191-202.
42. Zhang X, Burt HM, Mangold G, et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs. 1997;8:696-701.
43. Zhang X, Burt HM, Von Hoff D, et al. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 1997;40:81-86.
44. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18:2009-2014.
45. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108:241-250.
46. Park SR, Oh DY, Kim DW, et al. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep. 2004;12:1059-1064.
47. Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001;74:233-236.
48. Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res. 2001;7:3229-3238.
49. Sparreboom A, Wolff AC, Verweij J, et al. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin Cancer Res. 2003;9:151-159.
50. Fracasso PM, Picus J, Wildi JD, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2009;63:451-458.
51. Homsi J, Bedikian AY, Kim KB, et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009;19:238-242.
52. Bedikian AY, DeConti RC, Conry R, et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol. 2011;22:787-793.
53. Jones RJ, Hawkins RE, Eatock MM, et al. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol. 2008;61:435-441.
54. Hidalgo M, Aylesworth C, Hammond LA, et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol. 2001;19:2493-2503.
55. Kim JS, Amorino G P, Pyo H, Cao Q, Price JO, Choy H. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys. 2001;51:525-534.
56. Bilenker JH, Stevenson J P, Gallagher ML, Vaughn D, Cohen MB, O'Dwyer PJ. Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004;91:213-218.
57. Plummer R, Ghielmini M, Calvert P, et al. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res. 2002;8:2788-2797.
58. Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005;16:597-601.
59. Sessa C, Perotti A, Salvatorelli E, et al. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Eur J Cancer. 2004;40:563-570.
60. Villanueva C, Awada A, Campone M, et al. A multicentre doseescalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037-1045.
61. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263-1268.
62. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2008;26:639-643.
63. von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II Trial. J Clin Oncol. 2011;29:4548-4554.
64. Hosein PJ, de Lima Lopes G, Jr, Pastorini VH, et al. A Phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. Epub February 2, 2012.
65. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:111-115.
66. Ajani JA, Sun W, Rha SY, Baker JS, Mulcahy MF. Tesetaxel, a novel oral taxane, as second-line therapy for advanced gastroesophageal cancer: Activity in a dose-ranging study. ASCO Meeting Abstracts. 2012;30:47.
67. Moore MR, Jones C, Harker G, et al. Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. ASCO Meeting Abstracts. 2006;24:3591.
68. Kim HJ, Kim KH, Yun J, et al. Phase II clinical trial of Genexol(R) (paclitaxel) and carboplatin for patients with advanced non-small cell lung cancer. Cancer Res Treat. 2011;43:19-23.
69. Payne M, Ellis P, Dunlop D, et al. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol. 2006;1:984-990.
70. Sun W, Stevenson J P, Gallagher ML, et al. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res. 2003;9:5221-5227.
71. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-923.
72. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217.
73. Sparano JA, Vrdoljak E, Rixe O, et al. Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256-3263.
74. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinfunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-4461.
75. Krzakowski M, Ramlau R, Jassem J, et al. Phase III trial comparing vinfunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol. 2010;28:2167-2173.